Skip to main content

Table 1 Model parameters and estimations

From: Antiviral resistance during pandemic influenza: implications for stockpiling and drug use

parameter description baseline value references
1/μ A mean infectious period of asymptomatic infection 4.1 days [3, 6, 7]
1/μ U mean infectious period of untreated symptomatic infection 4.1 days [3, 6, 7]
1/μ T mean infectious period of treated symptomatic infection 4.1 days [3, 6, 7]
d U death rate of untreated symptomatic infection 0.002 day-1 [12, 19]
d T death rate of treated symptomatic infection 0.001 day-1 [12, 19]
d U,r death rate of resistant infection (low fitness) 0.0002 day-1 [12, 19]
d r,U death rate of resistant infection (high fitness) 0.0008 day-1 [12, 19]
δ A relative transmissibility of asymptomatic infection 0.142 [6, 7, 19]
δ T relative transmissibility of treated symptomatic infection 0.4 [3, 12, 19]
δ r relative transmissibility of resistant strain (high fitness) 0.9 [19, 27]
p probability of developing clinical symptoms 0.67 [6, 7]
α rate of emergence of de novo resistance 0.018 day-1 [19, 25]
γ rate of conversion between resistant mutants 0.0036 day-1 [19, 25]
q treatment level variable  
  1. Description of the model parameters with their values obtained from the published literature.